ECHEMINFO Conference on Advances in Drug Discovery and Design at Johns Hopkins, Baltimore, USA HALLE/SAALE, Germany, 09 February 2015 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical […]
HALLE/SAALE, Germany, 04 February 2015 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that Probiodrug’s CEO and […]
Presentation at Society for Neuroscience (SfN) and Poster at Clinical Trials on Alzheimer’s Disease (CtaD) HALLE/SAALE, Germany, 17 November 2014 – Probiodrug AG (“Probiodrug”), a biopharmaceutical […]
This announcement is not an offer to sell, or a solicitation of an offer to acquire any securities. This announcement is not a prospectus and investors […]
This announcement is not an offer to sell, or a solicitation of an offer to acquire any securities. This announcement is not a prospectus and investors […]
HALLE/SAALE, Germany, 31 October 2014 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s Disease, announces that on September 30, […]
• The share capital of Probiodrug AG is increased by EUR 1,475,409.00 from EUR 5,241,693.00 to EUR 6,717,102.00 • 1,475,409 New Shares have been issued • […]
HALLE/SAALE, Germany, October 29, 2014 – Probiodrug AG (“Probiodrug”), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces it is the Silver sponsor of […]
Probiodrug sammelt durch den erfolgreichen Börsengang an der Amsterdamer Börse Euronext 22,5 Mio. Euro ein